Literature DB >> 737252

Differences in platelet monoamine oxidase activity in subgroups of schizophrenic and depressive disorders.

P J Orsulak, J J Schildkraut, A F Schatzberg, J M Herzog.   

Abstract

Platelet monoamine oxidase (MAO) activity was measured in patients with nonaffective schizophrenic disorders (i.e., without prominent symptoms of depressions or manias), and in patients with schizophrenia-related depressions. MAO activity was significantly lower than control values in a subgroup of 16 patients with nonaffective schizophrenic disorders (most of whom were paranoid) characterized by the presence of auditory hallucinations and delusions. Platelet MAO activity was not reduced in 16 other nonaffective schizophrenic patients without auditory hallucinations. Platelet MAO activity was significantly higher than control values in a group of 8 depressed patients with schizophrenia-related depressions characterized by the presence of chronic asocial, eccentric, or bizarre behavior. These findings of differences in platelet MAO activity in clinically defined subgroups of nonaffective schizophrenic disorders and the schizophrenia-related depressive disorders may help to account for some of the discrepancies in findings among the various studies of platelet MAO activity in schizophrenic and affective disorders.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 737252

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  9 in total

1.  Some indices of the catecholamine and indoleamine metabolism in groups of patients with paranoid and simple forms of schizophrenia.

Authors:  N B Gamaleya
Journal:  Neurosci Behav Physiol       Date:  1985 Mar-Apr

Review 2.  Genetics and schizophrenic behavior.

Authors:  E Kahn
Journal:  Psychiatr Q       Date:  1980

3.  Reduced Platelet MAO-B Activity Is Associated with Psychotic, Positive, and Depressive Symptoms in PTSD.

Authors:  Senka Repovecki; Gordana Nedic Erjavec; Suzana Uzun; Lucija Tudor; Matea Nikolac Perkovic; Marcela Konjevod; Oliver Kozumplik; Dubravka Svob Strac; Zrnka Kovacic Petrovic; Ninoslav Mimica; Nela Pivac
Journal:  Biomolecules       Date:  2022-05-23

4.  Inhibition of monoamine oxidases by haloperidol and its metabolites: pharmacological implications for the chemotherapy of schizophrenia.

Authors:  J Fang; P H Yu; J W Gorrod; A A Boulton
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

5.  Monoamine oxidase activity and enzyme kinetics in three subpopulations of density-fractionated platelets in chronic paranoid schizophrenics.

Authors:  J J Mann; R D Kaplan; A Georgotas; E Friedman; M Branchey; S Gershon
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

6.  Platelet monoamine oxidase activity and schizophrenia--a myth that refuses to die?

Authors:  A Fleissner; R Seifert; K Schneider; W Eckert; B Fuisting
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1987

Review 7.  The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system.

Authors:  D C Ohuoha; T M Hyde; J E Kleinman
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Increased platelet monoamine oxidase activity in affective disorders.

Authors:  M A Reveley; V Glover; M Sandler; A Coppen
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

Review 9.  Human platelet monoamine oxidase activity in health and disease: a review.

Authors:  M Sandler; M A Reveley; V Glover
Journal:  J Clin Pathol       Date:  1981-03       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.